J Korean Endocr Soc.  2008 Feb;23(1):15-17. 10.3803/jkes.2008.23.1.15.

Naloxone Increases the Anorexic Effect of Melanocortin II

• Park S

• KMID: 2063545
• DOI: http://doi.org/10.3803/jkes.2008.23.1.15

Abstract

No abstract available.

MeSH Terms

Diethylpropion
Naloxone
Diethylpropion
Naloxone

Reference

1. Drazen DL, Woods SC. Peripheral signals in the control of satiety and hunger. Curr Opin Clin Nutr Metab Care. 2003. 6:621–629.

2. Druce MR, Small CJ, Bloom SR. Minireview: Gut peptides regulating satiety. Endocrinology. 2004. 145:2660–2665.

3. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005. 307:1909–1914.

4. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000. 404:661–671.

5. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004. 116:337–350.

6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994. 372:425–432.

7. Porte D Jr, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002. 60:S20–S29.

8. Shek EW, Scarpace PJ. Resistance to the anorexic and thermogenic effects of centrally administrated leptin in obese aged rats. Regul Pept. 2000. 92:65–71.

9. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role ofleptin in the neuroendocrine response to fasting. Nature. 1996. 382:250–252.

10. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995. 269:543–546.

11. Van HM, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest. 1997. 99:385–390.

12. Widdowson PS, Upton R, Buckingham R, Arch J, Williams G. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes. 1997. 46:1782–1785.

13. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 2004. 279:34733–34740.

14. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996. 348:159–161.

15. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA. 1997. 94:8878–8883.

16. Jonsson L, Skarphedinsson JO, Skuladottir GV, Atlason PT, Eiriksdottir VH, Franzson L, Schioth HB. Melanocortin receptor agonist transiently increases oxygen consumption in rats. Neuroreport. 2001. 12:3703–3708.

17. Kim YW, Choi DW, Park YH, Huh JY, Won KC, Choi KH, Park SY, Kim JY, Lee SK. Leptin-like effects of MTII are augmented in MSG-obese rats. Regul Pept. 2005. 127:63–70.

18. Brugman S, Clegg DJ, Woods SC, Seeley RJ. Combined blockade of both micro - and kappa-opioid receptors prevents the acute orexigenic action of Agouti-related protein. Endocrinology. 2002. 143:4265–4270.

19. Bae JH, Park YH, Kim SH, Park SY, Kim JY, Son JY, Huh JY, Won KC, Kim YW. Naloxone Increases the Anorexic Effect of MTII in OLETF Rats. J Kor Endocr Soc. 2008. 23:18–26.

20. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord. 2002. 26:Suppl 4. S29–S33.

21. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab. 2002. 16:717–742.

22. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000. 404:672–677.